Current Oncology

Scope & Guideline

Exploring Breakthroughs in Cancer Treatment

Introduction

Immerse yourself in the scholarly insights of Current Oncology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1198-0052
PublisherMDPI
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationCURR ONCOL / Curr. Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND

Aims and Scopes

Current Oncology is dedicated to advancing knowledge and practice in the field of oncology through the publication of high-quality research and reviews. The journal aims to cover a broad spectrum of topics related to cancer, including clinical, experimental, and translational research, providing a comprehensive resource for oncologists, researchers, and healthcare professionals.
  1. Clinical Oncology:
    Focuses on the clinical aspects of cancer treatment, including chemotherapy, radiotherapy, and surgical interventions, emphasizing evidence-based practices and patient outcomes.
  2. Translational Research:
    Highlights studies that bridge laboratory research and clinical application, exploring how scientific discoveries can inform and improve cancer treatment.
  3. Epidemiology and Public Health:
    Examines cancer incidence, risk factors, and outcomes across populations, addressing disparities in cancer care and promoting public health initiatives.
  4. Innovative Therapies:
    Covers emerging treatments such as immunotherapy, targeted therapy, and novel drug combinations, aiming to provide insights into the latest advancements in cancer management.
  5. Patient-Centered Care:
    Focuses on the psychosocial aspects of cancer care, including quality of life, survivorship, and the experiences of patients and caregivers in navigating the healthcare system.
  6. Health Economics and Policy:
    Investigates the economic implications of cancer treatments and policies, aiming to inform cost-effective strategies for cancer care delivery.
Current Oncology shows a dynamic evolution in its research focus, with several emerging themes reflecting the latest advancements and challenges in oncology. These trends highlight the journal's commitment to addressing contemporary issues in cancer care.
  1. Immunotherapy and Combination Therapies:
    A significant increase in research dedicated to immunotherapy, particularly in combination with other treatments, indicates a shift towards personalized and effective cancer treatments.
  2. Real-World Evidence and Outcomes Research:
    A growing emphasis on real-world evidence studies reflects a need to understand treatment effectiveness and patient experiences outside of clinical trial settings.
  3. Patient-Reported Outcomes and Quality of Life:
    An increasing focus on patient-reported outcomes and quality of life assessments suggests a recognition of the importance of holistic care in oncology.
  4. Telehealth and Virtual Care:
    The COVID-19 pandemic has accelerated the integration of telehealth in cancer care, leading to a rise in studies exploring its effectiveness and patient acceptance.
  5. Health Equity and Disparities:
    Emerging research addressing health disparities and access to care for marginalized populations highlights a critical need for equitable cancer treatment strategies.
  6. Genomic Profiling and Precision Medicine:
    The trend towards genomic profiling and precision medicine is prominent, with increasing studies examining the role of biomarkers in tailoring cancer therapies.

Declining or Waning

While Current Oncology continues to expand its focus on emerging and relevant areas in cancer research, certain themes appear to be declining in prominence. These waning scopes indicate a shift in research priorities and interests within the field.
  1. Traditional Chemotherapy Regimens:
    As newer therapies such as immunotherapy and targeted treatments gain popularity, traditional chemotherapy regimens are receiving less emphasis in recent publications.
  2. Single-Institution Studies:
    There is a noticeable decline in the publication of studies from single institutions, with a growing preference for multicenter trials that provide broader insights into treatment outcomes.
  3. Basic Science Research:
    Research focused solely on basic science and preclinical models is becoming less frequent, as the field shifts towards studies that emphasize translational and clinical relevance.
  4. Radiation Therapy Alone:
    The exploration of radiation therapy as a standalone treatment is decreasing, likely due to the increasing integration of combined modalities with systemic therapies.
  5. Conventional Screening Methods:
    Interest in traditional cancer screening methods is waning in favor of innovative approaches such as genomic screening and personalized medicine.

Similar Journals

BREAST

Empowering oncology with innovative insights.
Publisher: CHURCHILL LIVINGSTONEISSN: 0960-9776Frequency: 6 issues/year

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

Cancer Management and Research

Illuminating the complexities of oncology for better health.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

LANCET ONCOLOGY

Leading the way in oncology research and clinical excellence.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Breast Care

Advancing Breast Health Through Research and Innovation
Publisher: KARGERISSN: 1661-3791Frequency: 6 issues/year

Breast Care is a prominent academic journal published by KARGER, focusing on the dynamic fields of oncology and surgery. With an ISSN of 1661-3791 and an E-ISSN of 1661-3805, this peer-reviewed journal has established itself as an essential resource for researchers, clinicians, and students dedicated to advancing breast health. Based in Switzerland, it benefits from a strong academic reputation, evident in its impressive Scopus rankings—placing it in the 79th percentile in Surgery (Rank #115/551) and the 53rd percentile in Oncology (Rank #188/404). The journal is recognized for its rigorous exploration of current trends, innovations, and challenges in breast care, encompassing a wide scope from surgical techniques to oncological therapies. With a Q2 ranking in Oncology and a notable Q1 ranking in Surgery as of 2023, Breast Care not only contributes to the advancement of medical knowledge but also fosters interdisciplinary collaboration among healthcare professionals worldwide.

eCancerMedicalScience

Transforming cancer treatment with cutting-edge research.
Publisher: eCancer Global FoundationISSN: 1754-6605Frequency:

eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

Turk Onkoloji Dergisi-Turkish Journal of Oncology

Connecting researchers to transform cancer treatment and prevention.
Publisher: KARE PUBLISSN: 1300-7467Frequency: 4 issues/year

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

Translational Lung Cancer Research

Connecting researchers to revolutionize lung cancer care.
Publisher: AME PUBLISHING COMPANYISSN: 2218-6751Frequency: 6 issues/year

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Empowering researchers and practitioners in clinical oncology.
Publisher: OXFORD UNIV PRESSISSN: 0368-2811Frequency: 12 issues/year

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

CLINICAL ONCOLOGY

Fostering Collaboration for Breakthroughs in Cancer Treatment
Publisher: ELSEVIER SCIENCE LONDONISSN: 0936-6555Frequency: 6 issues/year

Clinical Oncology is a prestigious peer-reviewed journal published by Elsevier Science London, focusing on the dynamic fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an impressive impact factor reflecting its high-quality research contributions, the journal is ranked in the second quartile for oncology and the first quartile for radiology, underscoring its importance in advancing clinical knowledge and practice. Established in 1975, Clinical Oncology offers researchers, healthcare professionals, and students robust access to cutting-edge studies, reviews, and clinical trials that drive innovation and improve patient care. Based in the United Kingdom, the journal plays a vital role in disseminating significant findings, fostering collaboration, and enhancing education in the biosciences, particularly for those committed to addressing the challenges in cancer treatment and diagnostics. Given its rigorous selection criteria and broad readership, Clinical Oncology remains an essential resource for anyone dedicated to the fields of oncology and radiology.

Clinical Genitourinary Cancer

Exploring breakthroughs in cancer treatment and management.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.